24 Background 25 Dengue is the most prevalent arboviral disease, for which neither effective vaccines nor antivirals are available. 26 Clinical trials with Dengvaxia, the first licensed dengue vaccine, show the conventional in vitro plaque reduction 27 neutralization test (PRNT) failed to discriminate between neutralizing and non-neutralizing antibodies. A number 28 of human monoclonal antibodies (mAbs) were characterized by PRNT as being neutralizers of virus infectivity for 29 mammalian cells. 30 31 Methodolody/Principle findings 32 We developed a neutralization assay and tested the capacity of 12 mAbs to neutralize the infectiousness of dengue 33 patient viremic blood in mosquitoes. We identified minimum concentrations of a subset of mAbs required to 34 achieve dengue virus neutralization, and modelled the impact of a therapeutic mAb candidate on viremia. 35 36 Five of the 12 mAbs (14c10, 2D22, 1L12, 747(4)B7, 753(3)C10), all of which target quaternary epitopes, potently 37 inhibited dengue virus infection of Ae. aegypti. The potency of several mAbs was compromised in the context of 38 patients with secondary serological profiles, possibly reflecting competition between the exogenously-added mAbs 39 and the patient's own antibody responses at or near the target epitopes. The minimum concentrations that mAbs 40 neutralized DENV ranged from 0.1 -5 µg/mL. An Fc-disabled variant of mAb (14c10-LALA) was as potent as its 41 parent mAb. Within-host mathematical modelling suggests infusion of 14c10-LALA could bring about rapid 42 acceleration of viremia resolution in a typical patient. 43 44 Conclusions/Significance 45 These data delivered a unique assessment of anti-viral potency of a panel of human mAbs. Results support the 46 advancement of dengue virus neutralization assays, and the development of therapeutics against flaviviruses, to 47 which dengue virus and Zika virus belong. 48 3 49 Author summary 50 Dengue is the most prevalent arboviral disease affecting humans. There are no therapeutics for the disease. 51 Antibody-mediated immunity against dengue is also not well-understood, as shown by the failure of the 52 conventional neutralization assay used to predict the efficacy of Dengvaxia, the first licensed vaccine for the 53 disease. It is likely that the neutralization assay targets non-neutralizing antibodies, but there are no validation 54 assays available. To this end, we developed a novel virus neutralization assay, employing Aedes aegypti 55 mosquitoes and viremic blood from dengue patients, to examine the virus-neutralizing potency of 12 human-56 derived monoclonal antibodies (mAbs). While all of these mAbs neutralized dengue virus using the conventional 57 assay, seven of them failed to block dengue virus infections of mosquitoes using our assay. The remaining five 58 mAbs neutralized at least one serotype of dengue virus and the minimum neutralizing concentrations of range 59 from 0.1 -5 µg/mL. Using the minimum neutralizing concentration of a therapeutic mAb candidate, we 60 investigated the impact of the mAb on viremia using a mathematical model and found the mAb accelerated the 61 reduction of viremia. The results support the advancement of dengue virus neutralization assays, and the 62 development of therapeutics for dengue. 63 64 65 Key words 66 Human monoclonal antibodies, dengue virus (DENV), viremic blood, neutralization, mosquitoes, vaccine, 67 therapeutics 4 69
We developed a neutralization assay and tested the capacity of 12 mAbs to neutralize the infectiousness of dengue 33 patient viremic blood in mosquitoes. We identified minimum concentrations of a subset of mAbs required to 34 achieve dengue virus neutralization, and modelled the impact of a therapeutic mAb candidate on viremia. Author summary 50 Dengue is the most prevalent arboviral disease affecting humans. There are no therapeutics for the disease.
51
Antibody-mediated immunity against dengue is also not well-understood, as shown by the failure of the 52 conventional neutralization assay used to predict the efficacy of Dengvaxia, the first licensed vaccine for the 53 disease. It is likely that the neutralization assay targets non-neutralizing antibodies, but there are no validation 54 assays available. RNAemia level varied by serotype and was highest for DENV-1 ( Fig S1) . the DENV-1 specific mAb 14c10 was unaffected by pre-existing DENV-reactive IgG (Fig 2) , suggesting that epitope-220 binding competition with other antibodies was less relevant to serotype-specific mAbs. was just as potent as the parent mAb (Fig 3) . DENV-1 infection was completely inhibited in mosquitoes by 747(4)B7 237 at 3.7 µg/mL and 0.37 µg/mL, but not at lower doses, and the mAb generally failed to block DENV-4 infection at all 238 concentrations tested ( Fig S2) . 753(3)C10 was less potent than 747(4)B7 against DENV-1, blocking only at the 239 highest concentration tested, 5 µg/mL. 753(3)C10 also blocked the infectivity of DENV-4 viremic blood at 5 µg/mL, 240 but failed to neutralize virus when diluted any further ( Fig S3) . 
Modelled outcomes of therapeutic application of a potent, virus neutralizing mAb on DENV viremia
249 In a simplistic model, a blood concentration of 0.1 µg/mL mAb could be achieved in a 70 kg person with 5.5 L of 250 blood, by intravenous infusion of 7 µg of mAb per kg bodyweight. For the majority of individuals at the 10,000-fold 251 accelerated clearance, viremia immediately fell and continued to decline to undetectable levels 3-5 days before 252 viremia would have been resolved naturally (Fig 4) . A few individuals however observed a two-phase decline. At 253 100-fold, an immediate decline happened for many individuals, however a larger proportion of individuals saw a 254 two-phase decline (Fig S4) . This two-phase decline was observed when, at the point of mAb administration, the 255 total antibody, comprising patient's antibody plus 14c10-LALA was not yet sufficiently high to cause viral titers to The magnitude of virus neutralization mediated by some mAbs was striking. For example, in acute viremic blood 292 samples that contained >1,000 times the mosquito infectious dose of DENV-1 ( Fig S1) Table S1 . Previously characterized properties of tested monoclonal antibodies (mAbs) 433 434 Table S2 . Neutralization capacity of all monoclonal antibodies (mAbs) in the viremic blood neutralization assay 435 (ViBNA)
